Osaka, Japan

Toshihiko Nishiyama




Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2011-2020

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Toshihiko Nishiyama

Introduction

Toshihiko Nishiyama is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target various diseases. With a total of two patents to his name, his work has the potential to impact therapeutic strategies for immune and inflammatory diseases.

Latest Patents

Nishiyama's latest patents include an ethane-sulfonate salt of a quinoline derivative. This invention relates to a compound that exhibits Axl-inhibiting activity, making it useful as a prophylactic and therapeutic agent for immune diseases and cancer. His second patent involves a nitrogenated heterocyclic derivative that specifically binds to CCR5. This compound is beneficial for preventing and treating a range of diseases, including various inflammatory and immunological conditions, as well as infectious diseases.

Career Highlights

Throughout his career, Nishiyama has worked with prominent companies, including Ono Pharmaceutical Co., Ltd. His experience in the pharmaceutical industry has allowed him to develop innovative solutions that address critical health issues. His contributions to drug development are recognized within the scientific community.

Collaborations

Nishiyama has collaborated with notable colleagues such as Shinya Kusuda and Kazuya Hashimura. These partnerships have facilitated the advancement of his research and the successful development of his patented inventions.

Conclusion

Toshihiko Nishiyama's work exemplifies the impact of innovation in the pharmaceutical industry. His patents reflect a commitment to addressing significant health challenges through scientific research and collaboration.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…